Bright Minds Biosciences (DRUG) Share-based Compensation (2020 - 2026)
Bright Minds Biosciences' (DRUG) quarterly Share-based Compensation came in at $878672.4 in Q1 2026, up 104.71% YoY from $429236.4 in Q1 2025, and down 4.66% on a QoQ basis from $921592.8 in Q4 2025.
Bright Minds Biosciences (DRUG) Share-based Compensation (2020 - 2026) Analysis & Trends
Bright Minds Biosciences (DRUG) has 7 years of Share-based Compensation data on file, last reported at $878672.4 in Q1 2026.
- Quarterly Share-based Compensation rose 104.71% year-over-year to $878672.4 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.5 million (up 318.28% YoY) and the FY2025 annual result came in at $2.3 million, up 275.68% from the prior year.
- Share-based Compensation declined to $878672.4 in Q1 2026, from $921592.8 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $953650.7 in Q2 2025 to a low of $22158.3 in Q1 2023.
- A 5-year average of $355347.0 and a median of $229607.1 in 2022 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation plunged 92.33% — and 2023, when it jumped 1202.44%.
- Tracing DRUG's Share-based Compensation over 5 years: stood at $356669.6 in 2022, then sank by 54.91% to $160825.8 in 2023, then slipped by 21.49% to $126269.3 in 2024, then surged by 629.86% to $921592.8 in 2025, then dropped by 4.66% to $878672.4 in 2026.
- The last three Share-based Compensation figures came in at $878672.4 (Q1 2026), $921592.8 (Q4 2025), and $776796.1 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Bright Minds Biosciences | 733.05 Mn | 733.05 Mn | - | 1.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 878,672.44 |
| Mar 31, 2026 | 878,672.44 |
| Dec 31, 2025 | 921,592.84 |
| Dec 31, 2025 | 921,592.84 |
| Sep 30, 2025 | 776,796.07 |
| Sep 30, 2025 | 776,796.07 |
| Jun 30, 2025 | 953,650.69 |
| Jun 30, 2025 | 953,650.69 |
| Mar 31, 2025 | 429,236.43 |
| Mar 31, 2025 | 429,236.43 |
| Dec 31, 2024 | 126,269.35 |
| Dec 31, 2024 | 126,269.35 |
| Sep 30, 2024 | 154,116.42 |
| Sep 30, 2024 | 154,116.42 |
| Jun 30, 2024 | 134,486.72 |
| Jun 30, 2024 | 134,486.72 |
| Mar 31, 2024 | 168,194.02 |
| Mar 31, 2024 | 168,194.02 |
| Dec 31, 2023 | 160,825.82 |
| Dec 31, 2023 | 160,825.82 |